Dr. Ailis Tweed-Kent has been invited to be the Keynote Speaker for the Second Annual ACI Women Leaders in Life Sciences Law event, July 23 and 24 at the Omni Parker House in Boston.
Dr. Tweed-Kent is the founder and CEO of Cocoon Biotech, an early-stage biotech company that is in the process of developing a potential new therapy and/or delivery system in the treatment of osteoarthritis. In her talk, "CEO Spotlight: Extreme Complementarity - Building a Team with Diverse Skills and Personalities,” she will share her ideas on what it takes to create a successful business collaboration from scratch. She knows about this firsthand, as she formed the virtual company two years ago, recruiting a small team of bio-engineers, industry experts and physicians, raising seed funding, and securing exclusive patent rights. Cocoon Biotech is developing smooth, durable microscopic ball bearings made from natural silk, which can be administered directly into the knee joint to lubricate and locally release medication to treat pain and potentially delay progression of the disease. The company has completed initial efficacy and safety animal studies for its silk injectable osteoarthritis treatment, developed new intellectual property, raised initial seed financing, and started down the path of product development.
"But perhaps, most importantly,” according to Dr. Tweed-Kent, "we have built a high-impact other-orientated empowered team, one that embraces a radical and inspiring framework built on extreme complementarity."
Cocoon’s business plan already has received many honors. Earlier in 2015, Cocoon was selected as the New England region Startup of the Year at UNC Chapel Hill’s Venture Capital Investment Competition. Shortly after that, Dr. Tweed-Kent was recognized by Medtech Boston as one of 40 Under 40 Healthcare Innovators for her achievements with Cocoon. Most recently, the company graduated from Springboard Enterprises’ Health Innovation Hub 2015 as one of 11 women-led companies nationally, and gained recognition from Tufts University’s Tech Transfer office as the featured start-up of the year. In addition, Amgen has recognized Cocoon’s potential and has invited the company to use it’s lab facility free of charge for a year, beginning this fall.
To learn more about Dr. Tweed-Kent and Cocoon Biotech, please visit the Tufts Transfer web site at http://techtransfer.tufts.edu/ and the Cocoon website at http://www.cocoonbiotech.com.
If you would like to contact Dr. Tweed-Kent directly, feel free to do so at ailis@cocoonbiotech.com or her cell 413-822-2456.
Help employers find you! Check out all the jobs and post your resume.
Dr. Tweed-Kent is the founder and CEO of Cocoon Biotech, an early-stage biotech company that is in the process of developing a potential new therapy and/or delivery system in the treatment of osteoarthritis. In her talk, "CEO Spotlight: Extreme Complementarity - Building a Team with Diverse Skills and Personalities,” she will share her ideas on what it takes to create a successful business collaboration from scratch. She knows about this firsthand, as she formed the virtual company two years ago, recruiting a small team of bio-engineers, industry experts and physicians, raising seed funding, and securing exclusive patent rights. Cocoon Biotech is developing smooth, durable microscopic ball bearings made from natural silk, which can be administered directly into the knee joint to lubricate and locally release medication to treat pain and potentially delay progression of the disease. The company has completed initial efficacy and safety animal studies for its silk injectable osteoarthritis treatment, developed new intellectual property, raised initial seed financing, and started down the path of product development.
"But perhaps, most importantly,” according to Dr. Tweed-Kent, "we have built a high-impact other-orientated empowered team, one that embraces a radical and inspiring framework built on extreme complementarity."
Cocoon’s business plan already has received many honors. Earlier in 2015, Cocoon was selected as the New England region Startup of the Year at UNC Chapel Hill’s Venture Capital Investment Competition. Shortly after that, Dr. Tweed-Kent was recognized by Medtech Boston as one of 40 Under 40 Healthcare Innovators for her achievements with Cocoon. Most recently, the company graduated from Springboard Enterprises’ Health Innovation Hub 2015 as one of 11 women-led companies nationally, and gained recognition from Tufts University’s Tech Transfer office as the featured start-up of the year. In addition, Amgen has recognized Cocoon’s potential and has invited the company to use it’s lab facility free of charge for a year, beginning this fall.
To learn more about Dr. Tweed-Kent and Cocoon Biotech, please visit the Tufts Transfer web site at http://techtransfer.tufts.edu/ and the Cocoon website at http://www.cocoonbiotech.com.
If you would like to contact Dr. Tweed-Kent directly, feel free to do so at ailis@cocoonbiotech.com or her cell 413-822-2456.
Help employers find you! Check out all the jobs and post your resume.
